The startup, which is backed by the venture arms of Sanofi, Roche and Novartis, is using dual adeno-associated viruses to ...

The company is paying $350 million upfront, and potentially $1.2 billion overall, for a radiopharmaceutical for prostate ...

Insmed shares rocketed on results for a pulmonary arterial hypertension drug that exceeded Wall Street expectations.